Vicus Capital
- SEC CIK
- 0001544806
- Latest filing
- Aug 5, 2026
JNJ holding history
Johnson & Johnson in every 13F filed by Vicus Capital, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
JNJ overviewAll 13F holders of JNJFull Q2 2026 holdings
- Shares (Q2 2026)
- 4,876
- Value
- $1.24M
- % of portfolio
- 0.1%
- Quarters held
- 20
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,876 | $1.24M | 0.1% | −18−0.4% | Reduced | Holders |
| Q1 2026 | 4,894 | $1.20M | 0.1% | −76−1.5% | Reduced | Holders |
| Q4 2025 | 4,970 | $1.03M | 0.1% | −1,235−19.9% | Reduced | Holders |
| Q3 2025 | 6,205 | $1.15M | 0.1% | +1,129+22.2% | Added | Holders |
| Q2 2025 | 5,076 | $775.3K | 0.1% | −8−0.2% | Reduced | Holders |
| Q1 2025 | 5,084 | $843.1K | 0.1% | −380−7.0% | Reduced | Holders |
| Q4 2024 | 5,464 | $790.2K | 0.1% | +104+1.9% | Added | Holders |
| Q3 2024 | 5,360 | $868.6K | 0.1% | −1,510−22.0% | Reduced | Holders |
| Q2 2024 | 6,870 | $1.00M | 0.1% | −206−2.9% | Reduced | Holders |
| Q1 2024 | 7,076 | $1.12M | 0.1% | +856+13.8% | Added | Holders |
| Q4 2023 | 6,220 | $974.9K | 0.1% | −1,653−21.0% | Reduced | Holders |
| Q3 2023 | 7,873 | $1.23M | 0.1% | +1,721+28.0% | Added | Holders |
| Q2 2023 | 6,152 | $1.02M | 0.1% | −394−6.0% | Reduced | Holders |
| Q1 2023 | 6,546 | $1.01M | 0.1% | −219−3.2% | Reduced | Holders |
| Q4 2022 | 6,765 | $1.20M | 0.1% | −6,180−47.7% | Reduced | Holders |
| Q3 2022 | 12,945 | $2.12M | 0.2% | +5,372+70.9% | Added | Holders |
| Q2 2022 | 7,573 | $1.34M | 0.2% | +903+13.5% | Added | Holders |
| Q1 2022 | 6,670 | $1.18M | 0.1% | +72+1.1% | Added | Holders |
| Q4 2021 | 6,598 | $1.14M | 0.1% | +6,598 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −7,911−100.0% | Sold out | Holders |
| Q1 2021 | 7,911 | $1.30M | 0.2% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.